Our clinical trials

Cantargia’s clinical program

Nadunolimab (CAN04)

The IL1RAP-binding antibody CAN04 is Cantargia’s lead asset and is investigated in multiple clinical trials in combination with chemotherapy or immunotherapy, summarized in the table below. The clinical program for CAN04 primarily focuses on pancreatic cancer (PDAC), non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).


Overview of Cantargia’s clinical studies for CAN04.


In the CAN10 project, a new antibody against IL1RAP is being developed for treatment of inflammatory and autoimmune diseases. The initial focus will be on two severe diseases: myocarditis and systemic sclerosis. CAN10 is currently in late-stage preclinical phase and the goal is to start the first clinical trial in the first half of 2023.